Dissemin is shutting down on January 1st, 2025

Published in

Taylor and Francis Group, Bioengineered, 4(2), p. 230-233

DOI: 10.4161/bbug.2.4.16114

Links

Tools

Export citation

Search in Google Scholar

The future of industrial antibiotic production: From random mutagenesis to synthetic biology

Journal article published in 2011 by Marnix H. Medema, Mohammad T. Alam, Rainer Breitling ORCID, Eriko Takano
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

atural products derived from the secondary metabolism of microbes constitute a cornerstone of modern medicine. Engineering bugs to produce these products in high quantities is a major challenge for biotechnology, which has usually been tackled by either one of two strategies: iterative random mutagenesis or rational design. Recently, we analyzed the transcriptome of a Streptomyces clavuligerus strain optimized for production of the ??-lactamase inhibitor clavulanic acid by multiple rounds of mutagenesis and selection, and discovered that the observed changes matched surprisingly well with simple changes that have been introduced into these strains by rational engineering. Here, we discuss how in the new field of synthetic biology, random mutagenesis and rational engineering can be implemented complementarily in ways which may enable one to go beyond the status quo that has now been reached by each method independently. ?? 2011 Landes Bioscience.